Pomalyst 2MG, 4MG - patient medication.
Ended Awarded Last action
- Contract number
- 36C24526N0348
- Awardee
-
Bristol-Myers Squibb Company UEI UFGKB2B71N12
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $16,422
Award facts
- Contract value 100% obligated
- $16,421.95 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Memphis, TN 38141, USA
Award details come from SAM.gov/FPDS.
About this award
Bristol-Myers Squibb Company received a delivery order valued at $16,421.95 under its Federal Supply Schedule contract with the Department of Veterans Affairs to supply Pomalyst (pomalidomide) 2mg and 4mg tablets for patient medication to Veterans Integrated Service Network 5, with a completion date of February 25, 2026. This order is issued under the Pharmaceuticals and Drugs (FSS-61-IB) master schedule contract (ID: 36F79724D0101), which carries a substantial ceiling value of $12.28 billion and extends through April 30, 2029. The delivery will be performed at the contracting location in Memphis, Tennessee, and the award carries no set-aside designation, reflecting Bristol-Myers Squibb's status as a large pharmaceutical manufacturer.
Pomalyst is a specialty oncology pharmaceutical used in the treatment of multiple myeloma and other hematologic malignancies, supporting the VA's mission to provide advanced cancer treatments to eligible veterans. This delivery order is consistent with Bristol-Myers Squibb's sustained engagement as a critical supplier within the Veterans Health Administration network, having received more than fifty documented delivery orders since 2022 across multiple Veterans Integrated Service Networks. The firm fixed-price contract structure provides the federal government access to negotiated pharmaceutical rates for a comprehensive range of oncology and immunotherapy products that represent current standards of care in specialized cancer treatment.
Quick answers
Who was awarded contract 36C24526N0348?
36C24526N0348 was awarded to Bristol-Myers Squibb Company by Veterans Integrated Service Network 5 (Veterans Health Administration) on February 19, 2026.
How much is contract 36C24526N0348 worth?
The government has obligated $16,422 on 36C24526N0348.
Is contract 36C24526N0348 an order under another contract?
Yes. 36C24526N0348 is a BPA call under 36F79724D0101-36E79726A0010, a blanket purchase agreement, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24526N0348 competed?
The extent of competition for 36C24526N0348 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award